Company Overview and News
KUALA LUMPUR (Sept 25): The FBM KLCI is expected to drift lower today, tracking the overnight losses at most global markets as worries of a protracted trade spat between China and the United States (US) is likely to weigh on investor sentiment.
KUALA LUMPUR (Sept 24): Based on corporate announcements and news flow today, companies in focus tomorrow (Tuesday, Sept 25) may include: CIMB, Bina Puri, Heng Huat, Bintai Kinden, Mynews, MLabs, Yinson, Berjaya Media and Parkson Holdings.
PKSGF 7293 6025 3368 0175 CIMDF 5932 5657 1023 5347 PKSGY TNABY TNABF
KUALA LUMPUR (Sept 24): Parkson Holdings Bhd said the sale of a 70% stake in Parkson Credit Sdn Bhd to its Hong Kong-listed subsidiary Parkson Retail Group Ltd will result in a smaller share of future contribution from the credit service business.
5657 PKSGF PKSGY 3368 BSMAF 1818
Parkson Holdings Bhd (Sept 14, 40.5 sen) Maintain neutral with a target price (TP) of 79 sen: Parkson Holdings Bhd has announced that its wholly-owned subsidiary, Parkson Credit Holdings Sdn Bhd (PCHSB), had disposed of a 70% stake in Parkson Credit Sdn Bhd (PCSB), to its 54.97%-owned subsidiary Parkson Retail Group Ltd (PRGL) for RM49 million. Upon completion, PRGL will own a 70% stake in PCSB while the remainder 30% will be owned by PCHSB, which means an effective interest of 68.
5657 PKSGF PKSGY 3368
KUALA LUMPUR: Parkson Holdings Bhd is divesting a 70% stake in its wholly-owned hire purchase unit, Parkson Credit Sdn Bhd, to Hong Kong-listed subsidiary Parkson Retail Group Ltd for RM49 million.
5657 5228 PKSGF PKSGY 3368 BSMAF 1818
KUALA LUMPUR (Sept 13): Based on corporate announcements and news flow today, stocks in focus on Friday (Sept 14) may include: Westports Holdings Bhd, Bermaz Auto Bhd, Yee Lee Corp Bhd, Tasco Bhd, SMTrack Bhd, Panpages Bhd, Axiata Group Bhd, FGV Holdings Bhd, Binasat Communications Sdn Bhd, Parkson Holdings Bhd and Dataprep Holdings Bhd.
PKSGF PTXAF 3368 5246 5584 5657 PKSGY 8338 6888 PTXKY AXXTF BSMAF 1818
Parkson Holdings Bhd (Aug 28, 43.5 sen) Maintain outperform with a lower target price (TP) of 81 sen: Parkson Holdings Bhd’s core net loss (CNL) of RM17.9 million for financial year 2018 (FY18) ended June 30, 2018 narrowed, compared with a CNL of RM224 million in FY17, versus our/consensus RM35.8 million/RM30 million full-year net profit forecasts. We consider the result as below our expectations due to lower-than-expected sales from China and an unexpected store closure (Anshan Parkson, which was closed for 24 days in April due to a fire hazard).
KUALA LUMPUR (Aug 27): Parkson Holdings Bhd narrowed its net loss to RM71.89 million in the fourth financial quarter ended June 30, 2018 (4QFY18) from RM97.75 million a year ago, on lower operating losses and tax expenses.
5657 BSMAF 1818
KUALA LUMPUR (June 29): Based on corporate announcements and news flow today, stocks in focus for Monday (July 2) may include the following: Malaysia Airports Holdings Bhd, Sapura Energy Bhd, MBM Resources Bhd, Parkson Holdings Bhd and Green Packet Bhd.
O9E SPXCF PMOIF 0082 PMO 5983 5014 S68 5657 SPXCY MYPRY BSMAF PMOIY 1818
KUALA LUMPUR (June 29): Parkson Holdings Bhd's 67.96%-owned subsidiary Parkson Retail Asia Limited, which is listed on the Singapore Exchange, has appointed Chang Chae Young as the chief executive officer (CEO) for its newly-formed Indochina Operations.
5657 O9E SPXCY SPXCF BSMAF S68 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...